Trials / Terminated
TerminatedNCT04470622
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Heron Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aprepitant injectable emulsion | Aprepitant injectable emulsion, once daily (QD) for 14 days. |
| DRUG | Saline Placebo | Saline Placebo, once daily (QD) for 14 days. |
Timeline
- Start date
- 2020-07-20
- Primary completion
- 2021-04-09
- Completion
- 2021-06-03
- First posted
- 2020-07-14
- Last updated
- 2026-03-02
- Results posted
- 2022-08-30
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04470622. Inclusion in this directory is not an endorsement.